Sotoxen 120 mg (Sotorasib) Tablets

Sotoxen 120 mg contains sotorasib, a targeted anticancer medicine known as a KRAS G12C inhibitor. It is used for eligible adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumor has a confirmed KRAS G12C mutation.

Sotorasib works by selectively targeting the abnormal KRAS G12C protein involved in cancer-cell signaling. By binding to the mutated KRAS G12C protein, it helps prevent the signaling activity that can contribute to uncontrolled tumor-cell growth and survival.

The medicine may be prescribed when the patient's cancer has specific molecular characteristics and treatment with sotorasib is considered appropriate by an oncology specialist. Treatment decisions depend on factors such as mutation status, previous therapies, overall health, and applicable clinical guidelines.

Therapeutic effects may include:

• Targeted inhibition of KRAS G12C signaling
• Suppression of cancer-cell growth pathways
• Potential slowing of tumor progression
• Disease-control support in appropriately selected NSCLC patients

Sotorasib is a prescription oncology medicine and should be used only under appropriate medical supervision.

Active Ingredient: Sotorasib 120 mg

Drug Class: KRAS G12C inhibitor

Dosage Form: Film-coated tablet

Each tablet contains Sotorasib 120 mg as the active pharmaceutical ingredient. The formulation may also contain inactive excipients used to provide the tablet's structure, stability, coating, and manufacturing characteristics.

For patients with allergies or sensitivities to pharmaceutical excipients, the complete ingredient list should be checked on the product packaging or official product information before use.

Recommended adult dosage:
The recommended dose of sotorasib is 960 mg taken orally once daily. This corresponds to eight 120 mg tablets once daily, unless the treating physician prescribes a different regimen because of adverse reactions or other clinical considerations.

How to take:

• Take the prescribed dose once daily at approximately the same time each day.
• Tablets may be taken with or without food.
• Swallow the tablets whole with water.
• Do not crush, chew, or split the tablets unless specifically instructed by a healthcare professional.
• Continue treatment according to the oncology specialist's treatment plan.

If a dose is missed:
If a scheduled dose is missed by 6 hours or less, take it when remembered. If more than 6 hours have passed, skip the missed dose and take the next dose at the regular time. Do not take two doses together to compensate for a missed dose.

Important: Dose interruptions, reductions, or permanent discontinuation may be required if significant adverse reactions occur. Any dose adjustment should be made by the treating healthcare professional.